SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Athira Pharma, Inc. on January 6, 2023. The filing discloses the entry into a material definitive agreement and provides preliminary financial condition information as of December 31, 2022. Note: The request metadata referenced "Leonabio, Inc.", but the filing text explicitly identifies the registrant as Athira Pharma, Inc.
Key Financial Metrics
- Cash and Investments: Approximately $245.2 million in cash, cash equivalents, and investments as of December 31, 2022.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
- Debt and Liquidity: No specific debt figures are disclosed in this report; liquidity is indicated by the cash position noted above.
Material Changes and Agreements
On January 6, 2023, the Company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and BTIG, LLC. This agreement establishes an "at-the-market" (ATM) offering program allowing the Company to sell its common stock through the agents. Key terms include:
- Compensation: Agents are entitled to 3.0% of the aggregate gross proceeds from each sale.
- Flexibility: The Company controls sale parameters, including share count, timing, and minimum price, and may suspend or terminate the agreement at any time.
- Registration: Shares will be issued under an effective shelf registration statement (Form S-3) filed in November 2021.
Outlook, Risks, and Management Commentary
The financial condition information provided ($245.2 million) is preliminary and unaudited, based on management's initial analysis and subject to further review and external audit. The filing notes that the Sales Agreement may be terminated by an Agent in the event of a material adverse change in the Company. No specific forward-looking guidance or operational outlook beyond the ATM program was included in this text.
Investor Verification Checklist
- Verify the final audited cash position for the year ended December 31, 2022, in the upcoming 10-K filing.
- Monitor the prospectus supplement and subsequent 8-K filings for actual share sales and proceeds generated under the new ATM agreement.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific limitations on daily sales volume and pricing floors.
- Confirm the Company's ongoing compliance with Nasdaq listing requirements given the potential for dilution from the ATM program.